Biosergen AB (FRA:8N1) Total Operating Expense : €2.10 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Biosergen AB Total Operating Expense?

Biosergen AB's Total Operating Expense for the three months ended in Sep. 2024 was €0.38 Mil. Biosergen AB's Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 was €2.10 Mil.

Biosergen AB Total Operating Expense Historical Data

The historical data trend for Biosergen AB's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosergen AB Total Operating Expense Chart

Biosergen AB Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Operating Expense

0.61

3.30

3.14

2.43

Biosergen AB Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Operating Expense	Get a 7-Day Free Trial											0.64	0.61	0.60	0.51	0.38

Biosergen AB Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.

Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.10 Mil.

Biosergen AB Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Biosergen AB's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosergen AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (FRA:8N1) » Definitions » Total Operating Expense

Comparable Companies

Traded in Other Exchanges

BIOSGN:Sweden

Address

Fogdevreten 2, Solna, SWE, 17165

Website

https://www.biosergen.net

Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway, and several other places worldwide. The company is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.

Biosergen AB Headlines

No Headlines